pDNA encoding human hepatocyte growth factor (HGF) has shown significant activity in clinical trials for the treatment of peripheral arterial disease [1,2], and was first approved in Japan in 2019 for use by intramuscular injection. Here, HGF is linked to peripheral arterial disease.